Introduction
Staphylococcus aureus is a globally important cause of healthcare-associated infections. Moreover, it is a very successful antimicrobial-resistance developer (1). Methicillin-resistant S. aureus is an important nosocomial pathogen in Turkey and many other countries (1,2). Nosocomial methicillin-resistant S. aureus (MRSA) infection rates differ according to countries, regions, and hospitals (1-4). Ten, 50, and 90 percentile methicillinresistance rate in S. aureus strains causing healthcareassociated infections in Turkish tertiary-care university hospitals were 8.05%, 43.24%, and 78.26% in 2012, respectively. The overall cumulative MRSA rate in the 373 hospitals was 53.88% (1672/3103) (5) . Periodical control of resistance rates in major nosocomial pathogens is important in the selection of empirical therapy regimens. In the present study it was aimed to evaluate the resistance patterns and incidence of microbiologically confirmed nosocomial bacteremia (MCNB)-related S. aureus strains between 2001 and 2013 retrospectively.
Materials and methods
Any patient in whom S. aureus was isolated in at least one set of blood cultures (sent to the bacteriology laboratory 72 h after hospital admission) was considered to have MCNB. Data of antibacterial resistance and hospital admission duration were extracted from the hospital database. Double or more isolates during each episode were counted as one episode. Resistance patterns in the 2001-2003 and 2011-2013 periods were compared by chisquare test. Blood cultures were performed on Bact/Alert (bioMérieux, Durham, NC, USA). Bacterial identification was performed by using automated API (bioMérieux). Oxoid antibiotic discs (oxacillin 1 µg, gentamicin 30 µg, levofloxacin 5 µg, erythromycin 15 µg, clindamycin 15 µg, penicillin 10 µg, England) were used to test antibacterial susceptibility via disc diffusion method by following the recommendations of the Clinical and Laboratory Standards Institute (6) .
In addition, the data related to the number of overall inpatients and the total patient days for each year between 2001 and 2013 were retrieved from the hospital database. By using these data, we calculated the nosocomial S. aureus/ MRSA and MSSA bacteremia incidence for every 1000 patient days and 1000 patients per year. The chi-square test was used for the statistical analysis of susceptibility data.
Results
The 
Discussion
Antibiotic stewardship, education of hospital staff, effective utilization of microbiology laboratory, and seek and destroy policy as well as isolation of infected cases, hand hygiene, and limited in-hospital transfer of MRSA cases are among the most important measures for MRSA prevention (7) . Recent Infectious Diseases Society of America guidelines suggest preauthorization and/or prospective audit and feedback over no such interventions (strong recommendation, moderate-quality evidence) (8) . Compatible with these suggestions, in 2003, the Turkish Ministry of Finance, which is responsible for reimbursement of over 90% of the Turkish population's health expenditures, released a new budget application instruction for regulating the usage of parenteral antibiotics inside and outside of the hospitals. According to this instruction, the reimbursement of parenteral vancomycin, teicoplanin, meropenem, imipenem, piperacillin/ tazobactam, and ticarcillin/clavulanate is restricted without prior approval from an Infectious Diseases Specialist (IDS). Reimbursement of ceftriaxone, cefotaxime, ceftizoxime, cefoperazone, ceftazidime, cefoperazone/sulbactam, cefepime, ciprofloxacin, levofloxacin, netilmicin, amikacin, and isepamicin is unlimited, when prescribed for the first 72 h of the treatment, for all specialists (except general practitioners) but further usage required IDS approval. The other antimicrobials are reimbursed without any restriction by prescription of any medical doctor (1,9). Decrease in cost and changes in antimicrobial resistance are known results of antibiotic restriction policies (1,9-11). The intervention resulted in decreased use of third generation cephalosporins and quinolones (1,9). Decreases in overall antibiotic consumption as well as cephalosporins and quinolones are associated with decreases in MRSA incidence and MRSA rates (1,9). Although the hand hygiene compliance rate was traditionally not high (12), our Nosocomial Infection Control Committee is working hard on the issue and the hand hygiene compliance rates increased to higher levels (29% in 2014 July-September period, unpublished data). The infection control committee does not implement routine contact isolation for MRSA but vancomycin-resistant enterococci and colistin-resistant Acinetobacter and Pseudomonas as well as carbapenem-resistant Enterobacteriaceae. A seek and destroy policy around the hospital was not implemented except in neurosurgery (since 2008 July) during the study period (13) . During the 13 years there were several epidemics due to VRE and carbapenem-resistant Enterobacteriaceae, which are on the rise in other parts of Turkey in recent years. Universal isolation precautions were implemented for management of these epidemics. Several interventional programs are planned for improving the situation. Personnel screening is not implemented routinely except for VRE epidemics. A self-decrease (by the increase in Acinetobacter infections) or a subtle effect of the prevention methods during these epidemics cannot be excluded. However, in our opinion, the most probable reason for the MRSA rate decrease until 2005 is the effect of antimicrobial stewardship efforts, which resulted in decreased third generation cephalosporin and quinolone consumption. We may speculate that the plateau period of MRSA rates after that year may be due to the limitations of the antibiotic stewardship alone. In addition, the increase in the patient number and patient days with the start of the hospital service to all people covered by general social security (until that year only state employees could come to the hospital directly/without any referral) might have contributed to the situation. The increase in the general incidence during a simultaneous decrease in MRSA rates through 2004-2005 might have been due to the higher requests for infectious diseases consultation, resulting in more requests for blood cultures. The second downward trend is probably mostly due to the introduction of nonglycopeptide antibiotics such as linezolid, daptomycin, tigecycline, and colistin for both gram-positive and gramnegative bacteria, which decreased the overall glycopeptide and beta-lactam consumption. Hence, the lower antibiotic pressure might have contributed to the decrease in the resistance (1).
Our study has several limitations. The study is based on retrospective data. In addition, it is possible that all patients with fever might have not been subjected to blood culture during the study period. Hence, all the presented data represent the overall MCNB but may not represent all the S. aureus bacteremia episodes. We did not evaluate the treatment regimens as well as outcomes of the MCNB. Despite these disadvantages, to the best of our knowledge this is the largest and the most comprehensive set of data regarding MCNB S. aureus and its incidence in Turkey.
According to results of this retrospective perspective of 13 years, there was a steady decrease in MRSA rates between 
